top of page

New Study Unveils Medication Challenges for Alpha-gal Syndrome Patients at ACC 2024

VeganMed, Inc.

Apr 8, 2024

A poster presentation at the American College of Cardiology (ACC) 73rd Annual Scientific Session & Expo highlights the challenges faced by individuals with Alpha-gal syndrome (AGS), revealing insights from social media discussions among AGS patients.

At the American College of Cardiology (ACC) 73rd Annual Scientific Session & Expo, a poster presentation shed light on the medication challenges faced by individuals with Alpha-gal Syndrome (AGS). Affecting over 450,000 people in the US, AGS is triggered by a sugar molecule found in mammals, complicating medication management due to the prevalence of animal-derived ingredients.


The study analyzed social media discussions from three AGS support groups, revealing that medication-related posts were nearly as common as food-related posts. Key findings highlighted frequent mentions of antihistamines and pain relievers, such as diphenhydramine and ibuprofen, which often contain animal-derived components.


The researchers emphasized the urgent need for transparent medication labeling to aid AGS patients in identifying safe treatments and managing their condition more effectively.


For more details, contact: info@veganmed.org


To view the poster visit: https://www.veganmed.org/post/medication-insights-from-alpha-gal-social-media-groups

bottom of page